Food and Drug Administration officials said Tuesday that a data review of the AIDS drug abacavir revealed no greater risk of heart attacks than other HIV medicines. Doctors should continue to prescribe abacavir as directed, the agency said. FDA's analysis included 26 clinical trials and began in 2008 after studies showed conflicting information about a possible link to heart attacks. Abacavir, a nucleoside reverse transcriptase inhibitor, is in the combination treatments Ziagen, Trizivir, and Epzicom.
Back to other news for March 2011